A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started a side hustle to afford it.

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, not just the glucose impact of individual meals, they’ve been designed, largely thanks to Knudsen’s work, with slight changes to allow them to hang out in the blood longer than GLP-1 normally does.

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 drugs, and whether they're safe.

In the logistic regression model of the top 20 factors, significant associations for semaglutide initiation included being female (adjusted odds ratio, 2.30), using certain medication classes including antidepressants (adjusted odds ratio, 1.62), and being covered by a point-of-service plan (adjusted odds ratio, 1.78).

The company emphasised that it is ready to meet the growing demand for drug-device combinations and biologics, with semaglutide formulations being a focal point

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential impact on CKD.

Semaglutide is a powerful aid for managing weight and Type 2 diabetes, but it’s not a free pass to stick with old habits—or skip taking action altogether. If you’ve been struggling with weight loss, you know how challenging it can be to balance your appetite,

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than adults receiving semaglutide 2.4 mg, according to top-line results from the STEP UP phase 3b trial.

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as good as those in the trials cited above, however, the speed at which they were achieved has investors cheering, and Novo Nordisk stock is up 7.7% through 10:50 a.m. Friday morning.

Semaglutide (known by its brandname Ozempic) has gained widespread attention for its weight loss benefits, but is officially approved for managing type 2 diabetes. While there is currently limited dat

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an obesity drug.